Namilumab and infliximab being tested as possible COVID-19 therapy

Namilumab, a monoclonal antibody targeting GM-CSF (in the late stages of development for use in rheumatoid arthritis and ankylosing spondylitis), and infliximab, are two of four drugs being investigated in the CATALYST trial.

Source:

Reuters Health